Strategies for achieving multiple layers of selectivity in gene therapy

Molecular Medicine Today

Volumn 4, Issue 2, 1998, Pages 84-92

  Vile, R G ^a   Sunassee, K ^a   Diaz, R M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOPROTEIN GP 120; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; PLASMID DNA; PROTEIN P53; TRANSCRIPTION FACTOR; VIRUS VECTOR;

ANTIBODY SPECIFICITY; CANCER IMMUNOTHERAPY; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; NONHUMAN; PLASMID; REVIEW; TUMOR CELL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031934438     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(97)01157-X     Document Type: Article

References (42)

1. Simons J.W. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Res. 57 1997 1537 1546
2. Bordignon C. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients Science 270 1995 470 475
3. Nabel G.J. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans Proc. Natl. Acad. Sci. U. S. A. 90 1993 11307 11311
4. Crystal R.G. Transfer of genes to humans: early lessons and obstacles to success Science 270 1995 404 410
5. Russell S.J. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus J. Virol. 66 1992 2821 2828
6. Bischoff J. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373 376
7. Andreansky S. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors Cancer Res. 57 1997 1502 1509
8. Bergelson J.M. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 Science 275 1997 1320 1323
9. Weiss R.A. Chetankuma S.T. Retrovirus receptors Cell 82 1995 531 533
10. Dropulic B. Jeang K.T. Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention Hum. Gene Ther. 5 1994 927 939
11. Gougeon M-L. New concepts in AIDS pathogenesis AIDS Res. Hum. Retroviruses 4 1993 287 289
12. Miller D.G. Gene transfer by retro virus vectors occurs only in cells that are actively replicating at the time of infection Mol. Cell. Biol. 10 1990 4239 4242
13. Culver K.W. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors Science 256 1992 1550 1552
14. Rosenberg S.A. The development of gene therapy for the treatment of cancer Ann. Surg. 218 1993 455 464
15. Hwu P. In vivo antitumour activity of T cells redirected with chimeric antibody/T-cell receptor genes Cancer Res. 55 1995 3369 3373
16. Chen S-Y. Generation of a new class of tumor-specific killer cells Vector Targeting Strategies for Therapeutic Gene Delivery 1997 Cold Spring Harbor Laboratory 15
17. Curiel D. Opening address Vector Targeting Strategies for Therapeutic Gene Delivery 1997 Cold Spring Harbor Laboratory
18. Curiel D.T. Adenovirus facilitation of molecular conjugate-mediated gene transfer Prog. Med. Virol. 40 1993 1 18
19. Goldman C.K. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor Cancer Res. 57 1997 1447 1451
20. Cosset F-L. Russell S.J. Targeting retrovirus entry Gene Ther. 3 1996 946 956
21. Peng K.W. A gene delivery system activatable by disease-associated matrix metalloproteinases Hum. Gene Ther. 8 1997 729 738
22. Valesia-Wittman S. Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding EMBO J. 16 1997 1214 1223
23. Michael S.I. Addition of a short peptide ligand to the adenovirus fiber protein Gene Ther. 2 1995 660 668
24. Gallay P. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase Cell 83 1995 569 576
25. Miller N. Vile R.G. Targeted vectors for gene therapy FASEB J. 9 1995 190 199
26. Naldini L. In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector Science 272 1996 263 266
27. Lin K-Y. Treatment of established tumors with a novel vaccine that enhances major histocompatiblity class II presentation of tumor antigen Cancer Res. 56 1996 21 26
28. Elliot G. O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein Cell 88 1997 1 20
29. Moolten F.L. Cupples L.A. A model for predicting the risk of cancer consequent to retroviral gene therapy Hum. Gene Ther. 3 1992 479 486
30. Miller N. Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy Hum. Gene Ther. 8 1997 803 815
31. Vile R.G. Hart I.R. In vitro and in vivo targeting of gene expression to melanoma cells Cancer Res. 53 1993 962 967
32. Vile R.G. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component Cancer Res. 54 1994 6228 6234
33. Vile R.G. Tumour specific gene expression Semin. Cancer Biol. 5 1994 429 436
34. Dillon N. Grosveld F. Transcriptional regulation of multigene loci: multilevel control Trends Genet. 9 1993 134 137
35. Ring C.J.A. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter Gene Ther. 3 1996 1094 1103
36. Schedl A. A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice Nature 362 1993 258 261
37. Kochanek S. A new adenoviral vector: replacement of all viral coding sequences with 28kb of DNA independently expressing both full-length dystrophin and β-galactosidase Proc. Natl. Acad. Sci. U. S. A. 93 1996 5731 5736
38. Gossen M. Transcriptional activation by tetracylines in mammalian cells 268 1995 1766 1769
39. Vile R.G. Chong H. Immunotherapy: combinatorial molecular immunotherapy — a synthesis and suggestions Cancer Metastasis Rev. 15 1996 351 364
40. Moolten F.L. Drug sensitivity (‘suicide’) genes for selective cancer chemotherapy Cancer Gene Ther. 1 1994 279 287
41. Russell S.J. Replicating vectors for gene therapy of cancer: risks, limitations and prospects Eur. J. Cancer 30A 1994 1165 1171
42. Yei S. In vivo evaluation for the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung Hum. Gene Ther. 5 1994 731 744